表紙
市場調査レポート

モノクロナール抗体に関する各種提携契約:契約条件・合意内容

Global Monoclonal Antibody Partnering Terms and Agreements 2010 to 2016: Deal Trends, Players, Financials and Forecasts

発行 Current Partnering, a division of Wildwood Ventures Limited 商品コード 256416
出版日 ページ情報 英文 510 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
モノクロナール抗体に関する各種提携契約:契約条件・合意内容 Global Monoclonal Antibody Partnering Terms and Agreements 2010 to 2016: Deal Trends, Players, Financials and Forecasts
出版日: 2016年03月02日 ページ情報: 英文 510 Pages
概要

当レポートでは、モノクロナール抗体に関する各種提携契約について調査分析し、近年における各種契約の動向、大規模契約および大手医薬品事業者による契約の概要、契約区分・開発ステージ・治療分野・技術タイプ別のディレクトリなどをまとめ、概略下記の構成でお届けいたします。

エグゼクティブサマリー

第1章 イントロダクション

第2章 モノクロナール抗体に関する各種契約動向

  • イントロダクション
  • 過去数年におけるモノクロナール抗体に関する提携
  • 大手製薬会社による契約活動
  • モノクロナール抗体に積極的ではない大手製薬会社
  • モノクロナール抗体に関する提携:契約タイプ別
  • モノクロナール抗体に関する提携:適応症別
  • モノクロナール抗体の平均契約条件

第3章 主要契約

  • イントロダクション
  • 主要契約:取引額別

第4章 大手製薬会社のモノクロナール抗体契約

  • イントロダクション
  • 大手製薬会社のモノクロナール抗体提携契約の利用法
  • 大手製薬会社のモノクロナール抗体提携企業プロファイル

第5章 大手バイオテクのモノクロナール抗体契約

第6章 モノクロナール抗体提携契約ディレクトリ

  • イントロダクション
  • 企業A-Z
  • 契約タイプ別
  • 開発ステージ別
  • 治療分野別

第7章 モノクロナール抗体契約:技術タイプ別

第8章 モノクロナール抗体の提携機会

  • オンラインパートナリング
  • パートナリングイベント
  • 関連資料

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: CP21131

The ‘Global Monoclonal antibody Partnering Terms and Agreements 2010 to 2016: Deal trends, players, financials and forecasts’ report provides a detailed understanding and analysis of how and why companies enter monoclonal antibody partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors monoclonal antibody technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest monoclonal antibody agreements announced in the healthcare sectors, covering:

  • Monoclonal antibodies
  • Murine mAb
  • Chimeric mAb
  • Humanized mAb
  • Human aAb

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all monoclonal antibody partnering deals announced since Jan 2010, including financial terms where available, including links to online deal records of actual monoclonal antibody partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of monoclonal antibody dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in monoclonal antibody dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading monoclonal antibody deals since 2010. Deals are listed by headline value, signed by big pharma, most active monoclonal antibody dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in monoclonal antibody dealmaking with a brief summary followed by a comprehensive listing of monoclonal antibody deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of monoclonal antibody partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 7 provides a comprehensive and detailed review of monoclonal antibody partnering deals signed and announced since Jan 2010. The chapter is organized by specific monoclonal antibody technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by monoclonal antibody partnering company A-Z, deal type definitions and monoclonal antibody partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in monoclonal antibody partnering and dealmaking since 2010. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of monoclonal antibody technologies and products.

Key benefits

‘Global Monoclonal antibody Partnering Terms and Agreements 2010 to 2016’ provides the reader with the following key benefits:

  • In-depth understanding of monoclonal antibodies deal trends since 2010
  • Access to headline, upfront, milestone and royalty data
  • Access to the structure of monoclonal antibodies agreements with numerous real life case studies
  • Comprehensive access to over 700 actual monoclonal antibodies deals entered into by the world's biopharma companies
  • Identify the leading monoclonal antibody partnering companies
  • Insight into the terms included in a monoclonal antibodies agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

‘Global Monoclonal antibody Partnering Terms and Agreements 2010 to 2016’ is intended to provide the reader with an in- depth understanding and access to monoclonal antibodies trends and structure of deals entered into by leading companies worldwide.

‘Global Monoclonal antibody Partnering Terms and Agreements 2010 to 2016’ includes:

  • Trends in monoclonal antibodies dealmaking in the biopharma industry since 2010
  • Analysis of monoclonal antibodies deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to over 700 monoclonal antibodies deal records
  • The leading monoclonal antibodies deals by value since 2010
  • Includes chimeric mAb, humanized mAb, human mAb and murine mAb deals and alliances since 2010

In ‘Global Monoclonal antibody Partnering Terms and Agreements 2010 to 2016’, the available deals are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Monoclonal antibodies type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The‘ Global Monoclonal Antibody Partnering Terms and Agreements 2010 to 2016’ report provides comprehensive access to available deals and contract documents for over 700 monoclonal antibody deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise monoclonal antibody rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How aresalesand payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in monoclonal antibody dealmaking

  • 2.1. Introduction
  • 2.2. Monoclonal antibody partnering over the years
  • 2.3. Most active monoclonal antibody dealmakers
  • 2.4. Monoclonal antibody partnering by deal type
  • 2.5. Monoclonal antibody partnering by therapy area
  • 2.6. Deal terms for monoclonal antibody partnering
    • 2.6.1. Monoclonal antibody partnering headline values
    • 2.6.2. Monoclonal antibody deal upfront payments
    • 2.6.3. Monoclonal antibody deal milestone payments
    • 2.6.4. Monoclonal antibody royalty rates

Chapter 3 - Leading monoclonal antibody deals

  • 3.1. Introduction
  • 3.2. Top monoclonal antibody deals by value

Chapter 4 - Most active monoclonal antibody dealmakers

  • 4.1. Introduction
  • 4.2. Most active monoclonal antibody dealmakers
  • 4.3. Most active monoclonal antibody partnering company profiles

Chapter 5 - Monoclonal antibody contracts dealmaking directory

  • 5.1. Introduction
  • 5.2. Monoclonal antibody contracts dealmaking directory

Chapter 6 - Monoclonal antibody dealmaking by technology type

  • Monoclonal antibodies
  • Chimeric mAb
  • Humanized mAb
  • Human mAb
  • Murine mAb

Chapter 7 - Partnering resource center

  • 7.1. Online partnering
  • 7.2. Partnering events
  • 7.3. Further reading on dealmaking

Appendices

Appendix 1 - Monoclonal antibody deals by company A-Z

Appendix 2 - Monoclonal antibody deals by stage of development

  • Discovery
  • Preclinical
  • Phase I
  • Phase II
  • Phase III
  • Regulatory
  • Marketed
  • Formulation

Appendix 3 - Monoclonal antibody deals by deal type

  • Asset purchase
  • Assignment
  • Bigpharma outlicensing
  • Co-development
  • Collaborative R&D
  • Co-market
  • Co-promotion
  • CRADA
  • Development
  • Distribution
  • Equity purchase
  • Evaluation
  • Grant
  • Joint venture
  • Licensing
  • Loan
  • Manufacturing
  • Marketing
  • Material transfer
  • Option
  • Promotion
  • Research
  • Settlement
  • Spin out
  • Sub-license
  • Supply
  • Technology transfer
  • Termination

Appendix 4 - Monoclonal antibody deals by therapy area

  • Cardiovascular
  • Central Nervous System
  • Dental
  • Dermatology
  • Gastrointestinal
  • Hematology
  • Hospital care
  • Immunology
  • Infectives
  • Metabolic
  • Oncology
  • Ophthalmics
  • Orphan disease
  • Pediatrics
  • Respiratory

Appendix 5 -Deal type definitions

  • About Wildwood Ventures
  • Current Partnering
  • Current Agreements
  • Recent report titles from Current Partnering

Table of figures

  • Figure 1: Therapeutic antibody definitions
  • Figure 2: Monoclonal antibody partnering since 2010
  • Figure 3: Active monoclonal antibody dealmaking activity- 2010 to 2016
  • Figure 4: Monoclonal antibody partnering by deal type since 2010
  • Figure 5: Monoclonal antibody partnering by disease type since 2010
  • Figure 6: Monoclonal antibody deals with a headline value
  • Figure 7: Monoclonal antibody deals with an upfront value
  • Figure 8: Monoclonal antibody deals with a milestone value
  • Figure 9: Monoclonal antibody deals with a royalty rate value
  • Figure 10: Top monoclonal antibody deals by value since 2010
  • Figure 11: Most active monoclonal antibody dealmakers 2010 to 2016
  • Figure 12: Online partnering resources
  • Figure 13: Forthcoming partnering eventsh
Back to Top